title: Dramatic transient improvement of metastatic BRAF(V600E)-mutated Langerhans cell sarcoma under treatment with dabrafenib.
authors.affiliation: Laboratoire de Pharmacologie Biologique, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, Paris, France Université Paris Diderot, Sorbonne Paris Cité, Paris, France INSERM U976, Paris, France.
authors.forename: Samia
authors.initials: S
authors.lastname: Mourah
authors.affiliation: Centre National de Référence de l'Histiocytose Langerhansienne, Service de Pneumologie, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, Paris, France.
authors.forename: Gwenaël
authors.initials: G
authors.lastname: Lorillon
authors.affiliation: Service de Pathologie, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, INSERM UMR_S1165, Paris, France.
authors.forename: Véronique
authors.initials: V
authors.lastname: Meignin
authors.affiliation: Service de Médecine Nucléaire, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, Paris, France.
authors.forename: Laetitia
authors.initials: L
authors.lastname: Vercellino
authors.affiliation: Service de Radiologie, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, Paris, France.
authors.forename: Constance
authors.initials: C
authors.lastname: de Margerie-Mellon
authors.affiliation: Département de Dermatologie, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, Paris, France.
authors.forename: Cécile
authors.initials: C
authors.lastname: Pages
authors.affiliation: Laboratoire de Pharmacologie Biologique, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, Paris, France.
authors.forename: Lauriane
authors.initials: L
authors.lastname: Goldwirt
authors.affiliation: Laboratoire de Génomique Fonctionnelle, Fondation Jean Dausset-Centre d'Etude du Polymorphisme Humain, Paris, France.
authors.forename: Alexandre
authors.initials: A
authors.lastname: How-Kit
authors.affiliation: Laboratoire d'Epigénétique, Centre National de Génotypage, Commissariat à l'énergie atomique et aux énergies alternatives-Institut de Génomique, Evry, France.
authors.forename: Jorg
authors.initials: J
authors.lastname: Tost
authors.affiliation: Département de Dermatologie, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, Paris, France Université Paris Diderot, Sorbonne Paris Cité, Paris, France INSERM U976, Paris, France.
authors.forename: Céleste
authors.initials: C
authors.lastname: Lebbe
authors.affiliation: Centre National de Référence de l'Histiocytose Langerhansienne, Service de Pneumologie, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, Paris, France Université Paris Diderot, Sorbonne Paris Cité, Paris, France Equipe de Recherche en Biostatistiques et Epidémiologie Clinique, INSERM U1153 Centre de Recherche INSERM Epidémiologie et Statistique Paris Sorbonne Cité (CRESS), Paris, France.
authors.forename: Abdellatif
authors.initials: A
authors.lastname: Tazi
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use; D001384:Azetidines / Q000008:administration & dosage; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D019008:Drug Resistance, Neoplasm; D057915:Drug Substitution; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use*; D007211:Indoles / Q000008:administration & dosage; D054752:Langerhans Cell Sarcoma / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D008198:Lymph Nodes / Q000000981:diagnostic imaging / Q000473:pathology; D020930:MAP Kinase Kinase Kinases / Q000037:antagonists & inhibitors / Q000096:biosynthesis / Q000235:genetics; D008297:Male; D008875:Middle Aged; D058990:Molecular Targeted Therapy; D064847:Multimodal Imaging; D020125:Mutation, Missense; D009363:Neoplasm Proteins / Q000037:antagonists & inhibitors* / Q000235:genetics; D010091:Oximes / Q000627:therapeutic use*; D010880:Piperidines / Q000008:administration & dosage; D017354:Point Mutation; D049268:Positron-Emission Tomography; D011241:Prednisone / Q000008:administration & dosage; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011518:Proto-Oncogene Proteins / Q000037:antagonists & inhibitors / Q000096:biosynthesis / Q000235:genetics; D048493:Proto-Oncogene Proteins B-raf / Q000037:antagonists & inhibitors* / Q000235:genetics; D012008:Recurrence; D013449:Sulfonamides / Q000008:administration & dosage; D014057:Tomography, X-Ray Computed; D000077484:Vemurafenib; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D000970:Antineoplastic Agents; D001384:Azetidines; D007093:Imidazoles; D007211:Indoles; D009363:Neoplasm Proteins; D010091:Oximes; D010880:Piperidines; D047428:Protein Kinase Inhibitors; D011518:Proto-Oncogene Proteins; D013449:Sulfonamides; D000077484:Vemurafenib; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; C482119:BRAF protein, human; D048493:Proto-Oncogene Proteins B-raf; D020930:MAP Kinase Kinase Kinases; C069937:MAP3K8 protein, human; C574276:cobimetinib; C561627:dabrafenib; D011241:Prednisone